A study from Olmstead county and the Mayo Clinic shows that multimorbidity and social factors predict higher rheumatoid arthritis (RA) flares and lower remission rates.
Dr. Jack Cush reviews the news and journal reports from RheumNow. This week - unemployment, diagnosing Sjogren's and a lot of ILD.
Dr. John Cush RheumNow
11 months ago
6 yr study of Dutch #SLE pts (n 221) - unemployment was high (54%) & increased over time. Employ
ed assoc w/ supervisor support, regular working hrs, skill discretion, decision authority. Unemployment most from SLE Sxs (63%) & assoc w/ older, less education, Dz Dur, organ
Dr. John Cush RheumNow
11 months ago
EHR analysis of Alaska Tribal Health System finds the prevalence of Sjögren's disease at 199 per 100K adults (primary SjD 129; secondary 70 (RA,SLE)). The age-adjusted incidence 16.6 per 100K Pt-Yrs. Only 5% had salivary gland Bx & 3% met 2016 ACR/EULAR or 2012 ACR criteria https://t.co/4tMdWIGTEi
Dr. John Cush RheumNow
11 months ago
Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease A matched cohort study from the Veterans Health Administration shows that RA patients have a >50% increased risk of lung cancer, a 3-fold higher risk of lung cancer in RA-ILD. https://t.co/Gjn2M2CNAO https://t.co/F231nz57NY
Dr. John Cush RheumNow
11 months ago
SMART study from India finally published. RCT compare split-dose to single-dose oral MTX, in 253 RA pts. Split dose was superior w/ significantly higher EULAR good response at 16 weeks; & reduced need for 2nd DMARD, but had more intolerance and transaminitis. https://t.co/4jBxP2GPZM
Dr. John Cush RheumNow
11 months ago
LTBI risk in rheumatic pts is high (22%). Metanalysis 18 studies, 12,167 rheum pts shows LTBI signif. incr w/ current smoking (OR 1.50), golimumab(OR 2.90), Chloroquine (OR 1.27), age >40 (OR 1.84), prior TB OR 3.26). LTBI not increased w/ RF, ADA, ETN, BCG, Pred, smoking, DM https://t.co/0PayHJqwDn
Dr. John Cush RheumNow
11 months ago
Retrospective French Health Data System Immune Checkpt inhibitor (ICI) study. Of 172,363 ICI-Rx adult pts, ICI myotoxicities at 6 months ranged from 0.7% -0.9%. ICI myocarditis & myositis incidence was 0.3%- 0.6%, co-occurring in ∼13–23%. ICI myotoxicity- 1-mo fatality was https://t.co/kOGKM8lC0H
Dr. John Cush RheumNow
11 months ago
Connective tissue disease associated with interstitial lung disease (CTD-ILD) market is estimated to be $5.9 Billion USD in 2024 and is projected to grow to 9.3 billion, driven by increase in autoimmune Dz, adoption of biologics, ongoing clinical anti-fibrotic trials https://t.co/UqshQgNOau
Dr. John Cush RheumNow
11 months ago
ILD Begins (8.29.2025)
Dr. Jack Cush reviews the news and journal reports from https://t.co/V10S4oVFsv. This week news on vaccines, safety of acetaminophen and more.
https://t.co/YlOK3X4hkW https://t.co/9cgcDn0xab
I'm a pulmonologist at the University of Kansas in Kansas City, and I'm excited to talk about one of my favorite topics: treatment complications in rheumatoid arthritis- associated interstitial lung disease or RA-ILD. One of the reasons I think this is a pressing and important topic is what we're dealing with here is a group of patients who have really poor outcomes, even with the significant advances that the rheumatology community's been able
Dr. John Cush RheumNow
11 months ago
Combined Therapy in Rheumatoid Arthritis Interstitial Lung Disease
RA-ILD is a major therapeutic evidence gap in treatment, affecting 8% of patients. It was often under-diagnosed, leading to more severe cases and inflated mortality rates. Despite advancements, RA-ILD, https://t.co/Q8mMxtBgZZ
A post hoc, pooled analysis of of rheumatoid arthritis (RA) clinical trials shows those received abatacept had a lower rate of Interstitial lung disease (ILD).
Australian researchers have shown that methotrexate (MTX) has another secondary, beneficial effect by significantly lowering systolic blood pressure, and contributes to its well docuented cardioprotive effecs.
